COVID-19 vaccine, Pfizer-BioNTech and Health Canada
Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and
Health Canada approves Pfizer-BioNTech's updated COVID-19 vaccine
BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
Pfizer, BioNTech's Omicron-Adapted Covid-19 Vaccine Gets E.U. Marketing Recommendation
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is one step closer to becoming available across the European Union.
Pfizer’s updated COVID-19 vaccine approved by Health Canada
The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 Omicron subvariant.
Novavax, COVID-19 vaccine
Dr Roland denies instilling fear about Pfizer vaccine
SEPANG: Dr Roland Victor, who is charged with making and initiating the transmission of offensive videos about the Covid-19 ...
New COVID-19 vaccine available after summer wave of infections in Kitsap, Washington
The Centers for Disease Control recommends everyone 6 months or older get a 2024-2025 COVID vaccine. The Food and Drug ...
S.A. had a COVID-19 summer and the winter surge is next. Can the new vaccine slow it?
A summer wave of cases locally and across the country may be on the decline and a vaccine targeting the latest variants is ...
Pfizer Stock Vs. AbbVie
In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
Moderna's updated COVID-19 vaccine is coming to Alberta, but Novavax shots are not
"Canada's current contract with Novavax only provides access to domestically manufactured vaccines, which Novavax has been unable to confirm for the 2024-25 season," a Health Canada spokesperson said ...
Yahoo Finance1d
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I
GSK secured the first US Food and Drug Administration (FDA) approval for an adult RSV vaccine in May 2023, called Arexvy.
ABRYSVO™: Pfizer Canada's Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults
ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial ...